• Resources Recycling
• /
• v.4 no.3
• /
• pp.2-9
• /
• 1995

The rccoverg and separation pracess of nikcl, vanadium and molybdenum from spent dcsulfilrizing catalyst ofpetrochemical rndustries was studied. Tnis process was canied out wet process which is consist of roasting, ammonialeaching and solve111 exDaction techniqcs. The metal ions of NI, V and Mo as vduable compollents were treated byroasting them a1 low lernperatuc, 400$^{\circ}$C in first dep, and then dlssah'ed nu1 at 80$^{\circ}$C wlth ammonium cabonate mlulion.Aftcr cooling them a1 room tempertaure, vanadium wa rccavered from mathcr iiquur in thc f n m of precipitate, sodiumvanadales The Secand slep, roasting the catalyst which is added sodium carbonate ul IOOO"C, was employed. Leachingwith distilled ~ a l e rga ve a iwo phase resultant, solutio~c~a ntaning Ni, V and Mo and solid residue containing sibca,alurmniu~n and iron. A solvcnt exlclction technique uslng vvriuus extractanls, MSP-8, TOIUC, LIX64Pi was eflecnve farthc extraclion and scparation ol thrcc mcfals from thc ammonical 11qou1 thc ammonical 11qou1.

• Tuberculosis and Respiratory Diseases
• /
• v.60 no.2
• /
• pp.171-179
• /
• 2006

Background : Despite the emerging danger of MDR-TB to human beings, there have only been a limited number of drugs developed to treat MDR-TB since 1970. This study investigated the cross-resistance rate between rifampicin (RFP) and rifabutin (RBU) in order to determine the efficacy of rifabutin in treating MDR-TB. In addition, the results of rifabutin were correlated with the rpoB mutations, which are believed to be markers for MDR-TB and RFP resistance. Methods : The MICs of RBU were tested against 126 clinical isolates of MDR-TB submitted to the clinical laboratory of National Masan TB Hospital in 2004. Five different concentrations ($10-160{\mu}g/ml$) were used for the MICs. The detection of the rpoB mutations was performed using a RFP resistance detection kit with a line probe assay(LiPA), which contains the oligonucleotide probes for 5 wide type and 3 specific mutations (513CCA, 516GTC, and 531TTG) The rpoB mutation was determined by direct sequencing. Results : The rate of cross-resistance between RFP and RBU was 70.5%(74/105) at $20{\mu}g/ml$ RBU(ed note: How much RFP?) Most mutations (86.3%) occurred in the 524~534 codons. The His526Gln, His526Leu, Leu533Pro, Gln513Glu, and Leu511Pro mutations(Ed note: Is this correct?) were associated with the susceptibilty to RBU. Conclusion : Based on the cross-resistance rate between RFP and RBU, RBU may be used effectively in some MDR-TB patients. Therefore, a conventional drug susceptibility test for RBU and a determination of the critical concentration are needed. However, rpoB gene mutation test may be have limited clinical applications in detecting RBU resistance.